Melatonin, noncoding RNAs, messenger RNA stability and epigenetics—evidence, hints, gaps and perspectives

International Journal of Molecular Sciences

Volumn 15, Issue 10, 2014, Pages 18221-18252

  Hardeland, Rüdiger ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Circadian; DNA methylation; Histone acetylation; Histone methylation; lncRNA; Melatonin; miRNA; piRNA; RNA deadenylases

Indexed keywords

CIRCADIAN RHYTHM SIGNALING PROTEIN; HISTONE DEACETYLASE; MELATONIN; MELATONIN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 183; MICRORNA 483; NOCTURNIN; PER1 PROTEIN; PER2 PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIWI INTERACTING RNA; PROTEIN BMAL1; SIRTUIN 1; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ANTIOXIDANT ACTIVITY; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; ENERGY EXPENDITURE; EPIGENETICS; GENE EXPRESSION; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; LIGHT DARK CYCLE; MENTAL DISEASE; METABOLIC DISORDER; NEOPLASM; NERVOUS SYSTEM DEVELOPMENT; NEUROPSYCHIATRIC DISORDER; NIGHT; NONHUMAN; OXIDATIVE STRESS; REVIEW; RNA STABILITY; ANIMAL; CHEMISTRY; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; METABOLISM;

ANIMALS; CIRCADIAN CLOCKS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MELATONIN; MENTAL DISORDERS; METABOLIC DISEASES; RNA STABILITY; RNA, MESSENGER; RNA, UNTRANSLATED;

EID: 84907841513     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151018221     Document Type: Review

References (198)

1. Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin-A pleiotropic, orchestrating regulator molecule. Prog. Neurobiol. 2011, 93, 350-384.
2. Reiter, R. J.; Tan, D.-X.; Mayo, J. C.; Sainz, R. M.; Leon, J.; Czarnocki, Z. Melatonin as an antioxidant: Biochemical mechanisms and pathophysiological implications in humans. Acta Biochim. Pol. 2003, 50, 1129-1146.
3. Pandi-Perumal, S. R.; Srinivasan, V.; Maestroni, G. J. M.; Cardinali, D. P.; Poeggeler, B.; Hardeland, R. Melatonin: Nature's most versatile biological signal? FEBS J. 2006, 273, 2813-2838.
4. Negi, G.; Kumar, A.; Sharma, S. S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: Effects on NF-κB and Nrf2 cascades. J. Pineal Res. 2011, 50, 124-131.
5. Korkmaz, A.; Rosales-Corral, S.; Reiter, R. J. Gene regulation by melatonin linked to epigenetic phenomena. Gene 2012, 503, 1-11.
6. Carrillo-Vico, A.; Lardone, P. J.; Álvarez-Sánchez, N.; Rodríguez-Rodríguez, A.; Guerrero, J. M. Melatonin: Buffering the immune system. Int. J. Mol. Sci. 2013, 14, 8638-8683.
7. Ehrlich, M.; Lacey, M. DNA methylation and differentiation: Silencing, upregulation and modulation of gene expression. Epigenomics 2013, 5, 553-568.
8. Mihan, K. N.; Chaillet, J. R. Cell and molecular biology of DNA methyltransferase 1. Int. Rev. Cell Mol. Biol. 2013, 306, 1-42.
9. Kulis, M.; Queirós, A. C.; Beekman, R.; Martín-Subero, J. I. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim. Biophys. Acta 2013, 1829, 1161-1174.
10. Van Otterdijk, S. D.; Mathers, J. C.; Strathdee, G. Do age-related changes in DNA methylation play a role in the development of age-related diseases? Biochem. Soc. Trans. 2013, 41, 803-807.
11. Zentner, G. E.; Henikoff, S. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Mol. Biol. 2013, 20, 259-266.
12. Kaelin, W. G., Jr.; McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 2013, 153, 56-69.
13. Gut, P.; Verdin, E. The nexus of chromatin regulation and intermediary metabolism. Nature 2013, 502, 489-498.
14. Jarome, T. J.; Lubin, F. D. Histone lysine methylation: A critical regulator of memory and behavior. Rev. Neurosci. 2013, 24, 375-387.
15. Zhang, Y.; Qu, L. Non-coding RNAs and the acquisition of genomic imprinting in mammals. Sci. China C 2009, 52, 195-204.
16. Morozowa, N.; Zinovyev, A.; Nonne, N.; Pritchard, L. L.; Gorban, A. N.; Harel-Bellan, A. Kinetic signatures of microRNA modes of action. RNA 2012, 18, 1635-1655.
17. Tay, Y.; Rinn, J.; Pandolfi, P. P. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014, 505, 344-352.
18. Li, L.; Liu, Y. Diverse small non-coding RNAs and RNA interference pathways. Methods Mol. Biol. 2011, 764, 169-182.
19. Wilson, R. C.; Doudna, J. A. Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 2013, 42, 217-239.
20. Ross, R. J.; Weiner, M. M.; Lin, H. PIWI proteins and PIWI-interacting RNAs in the soma. Nature 2014, 505, 353-359.
21. Liu, L.; Lowe, T. Small nucleolar RNAs and RNA-guided post-transcriptional modification. Essays Biochem. 2013, 54, 53-77.
22. Schoeftner, S.; Blasco, M. A. Chromatin regulation and non-coding RNAs at mammalian telomeres. Semin. Cell. Dev. Biol. 2010, 21, 186-193.
23. Lee, J. T. Epigenetic regulation by long noncoding RNAs. Science 2012, 338, 1435-1439.
24. Marchese, F. P.; Huarte, M. Long non-coding RNAs and chromatin modifiers: Their place in the epigenetic code. Epigenetics 2013, 9, 21-26.
25. Yang, L.; Froberg, J. E.; Lee, J. T. Long noncoding RNAs: Fresh perspectives into the RNA world. Trends Biochem. Sci. 2014, 39, 35-43.
26. Hacisuleyman, E.; Goff, L. A.; Trapnell, C.; Williams, A.; Henao-Mejia, J.; Sun, L.; McClanahan, P.; Hendrickson, D. G.; Sauvagneau, M.; Kelley, D. R.; et al. Topological organization of multichromosomal regions by the long intergenic noncoding RNA Firre. Nat. Struct. Mol. Biol. 2014, 21, 198-206.
27. Li, X.; Wu, Z.; Mei, Q.; Li, X.; Guo, M.; Fu, X.; Han, W. Long non-coding RNA HOTAIR, a driver of malignancy, predicts negative prognosis and exhibits oncogenic activity in oesophageal squamous cell carcinoma. Br. J. Cancer 2013, 109, 2266-2278.
28. Romero, R.; Tarca, A. L.; Chaemsaithong, P.; Miranda, J.; Chaiworapongsa, T.; Jia, H.; Hassan, S. S.; Kalita, C. A.; Cai, J.; Yeo, L.; et al. Transcriptome interrogation of human myometrium identifies differentially expressed sense-antisense pairs of protein-coding and long non-coding RNA genes in spontaneous labor at term. J. Matern. Fetal Neonatal Med. 2014, 27, 1397-1408.
29. Wang, Y.; Pang, W. J.; Wei, N.; Xiong, Y.; Wu, W. J.; Zhao, C. Z.; Shen, Q. W.; Yang, G. S. Identification, stability and expression of Sirt1 antisense long non-coding RNA. Gene 2014, 539, 117-124.
30. Green, C. B.; Douris, N.; Kojima, S.; Strayer, C. A.; Fogerty, J.; Lourim, D.; Keller, S. R.; Besharse, J. C. Loss of nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity. Proc. Natl. Acad. Sci. USA 2007, 104, 9888-9893.
31. Stubblefield, J. J.; Terrien, J.; Green, C. B. Nocturnin: At the crossroads of clocks and metabolism. Trends Endocrinol. Metab. 2012, 23, 326-333.
32. Godwin, A. R.; Kojima, S.; Green, C. B.; Wilusz, J. Kiss your tail goodbye: The role of PARN, Nocturnin, and Angel deadenylases in mRNA biology. Biochim. Biophys. Acta 2013, 1829, 571-579.
33. Niu, S.; Shingle, D. L.; Garbarino-Pico, E.; Kojima, S.; Gilbert, M.; Green, C. B. The circadian deadenylase Nocturnin is necessary for stabilization of the iNOS mRNA in mice. PLoS One 2011, 6, e26954.
34. Kloeden, P. E.; Rössler, R.; Rössler, O. E. Artificial life extension. The epigenetic approach. Ann. N. Y. Acad. Sci. 1994, 719, 474-482.
35. Korkmaz, A.; Topal, T.; Tan, D.-X.; Reiter, R. J. Role of melatonin in metabolic regulation. Rev. Endocr. Metab. Disord. 2009, 10, 261-270.
36. Korkmaz, A.; Ma, S.; Topal, T.; Rosales-Corral, S.; Tan, D.-X.; Reiter, R. J. Glucose: A vital toxin and potential utility of melatonin in protecting against the diabetic state. Mol. Cell. Endocrinol. 2012, 349, 128-137.
37. Hardeland, R.; Madrid, J. A.; Tan, D.-X.; Reiter, R. J. Melatonin, the circadian multioscillator system and health: The need for detailed analyses of peripheral melatonin signaling. J. Pineal Res. 2012, 52, 139-166.
38. Hardeland, R. Chronobiology of melatonin beyond the feedback to the suprachiasmatic nucleus-Consequences to melatonin dysfunction. Int. J. Mol. Sci. 2013, 14, 5817-5841.
39. Clokie, S. J. H.; Lau, P.; Kim, H. H.; Coon, S. L.; Klein, D. C. MicroRNAs in the pineal gland. miR-483 regulates melatonin synthesis by targeting arylalkylamine N-acetyltransferase. J. Biol. Chem. 2012, 287, 25312-23524.
40. Ben-Moshe, Z.; Alon, S.; Mracek, P.; Faigenbloom, L.; Tovin, A.; Vatine, G. D.; Eisenberg, E.; Foulkes, N. S.; Gothilf, Y. The light-induced transcriptome of the zebrafish pineal gland reveals complex regulation of the circadian clockwork by light. Nucleic Acids Res. 2014, 42, 3750-3767.
41. Green, C. B.; Besharse, J. C. Identification of a novel vertebrate circadian clock-regulated gene encoding the protein nocturnin. Proc. Natl. Acad. Sci. USA 1996, 93, 14884-14888.
42. Green, C. B. Molecular control of Xenopus retinal circadian rhythms. J. Neuroendocrinol. 2003, 15, 350-354.
43. Coon, S. L.; Munson, P. J.; Cherukuri, P. F.; Sugden, D.; Rath, M. F.; Møller, M.; Clokie, S. J. H.; Fu, C.; Olanich, M. E.; Rangel, Z.; et al. Circadian changes in long noncoding RNAs in the pineal gland. Proc. Natl. Acad. Sci. USA 2012, 109, 13319-1324.
44. 1 receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells. Eur. J. Pharmacol. 2008, 589, 45-48.
45. Esposito, T.; Magliocca, S.; Formicola, D.; Gianfrancesco, F. piR_015520 belongs to Piwi-associated RNAs regulates expression of the human melatonin receptor 1A gene. PLoS One 2011, 6, e22727.
46. Cheng, H. Y. M.; Papp, J. W.; Varlamova, O.; Dziema, H.; Russell, B.; Curfman, J. P.; Nakazawa, T.; Shimizu, K.; Okamura, H.; Impey, S.; et al. MicroRNA modulation of circadian clock-period and entrainment. Neuron 2007, 54, 813-829.
47. Mehta, N.; Cheng, H. Y. M. Micro-managing the circadian clock: The role of microRNAs in biological timekeeping. J. Mol. Biol. 2013, 425, 3609-3624.
48. Kocerha, J.; Faghihi, M. A.; Lopez-Toledano, M. A.; Huang, J.; Ramsey, A. J.; Caron, M. G.; Sales, N.; Willoughby, D.; Elmen, J.; Hansen, H. F.; et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc. Natl. Acad. Sci. USA 2009, 106, 3507-3512.
49. Alvarez-Saavedra, M.; Antoun, G.; Yanagiya, A.; Oliva-Hernandez, R.; Cornejo-Palma, D.; Perez-Iratxeta, C.; Sonenberg, N.; Cheng, H. Y. M. MicroRNA-132 orchestrates chromatin remodeling and translational control of the circadian clock. Hum. Mol. Genet. 2011, 20, 371-351.
50. Mustafi, D.; Kevany, B. M.; Genoud, C.; Bai, X.; Palczewski, K. Photoreceptor phagocytosis is mediated by phosphoinositide signaling. FASEB J. 2013, 27, 4585-4595.
51. Xu, S. B.; Witmer, P. D.; Lumayag, S.; Kovacs, B.; Valle, D. MicroRNA (miRNA) transcriptome of mouse retina and identification of a sensory organ-specific miRNA cluster. J. Biol. Chem. 2007, 282, 25053-25066.
52. Labialle, S.; Croteau, S.; Bélanger, V.; McMurray, E. N.; Ruan, X.; Moussette, S.; Jonnaert, M.; Schmidt, J. V.; Cermakian, N.; Naumova, A. K. Novel imprinted transcripts from the Dlk1-Gtl2 intergenic region, Mico1 and Mico1os, show circadian oscillations. Epigenetics 2008, 3, 322-329.
53. Powell, W. T.; Coulson, R. L.; Crary, F. K.; Wong, S. S.; Ach, R. A.; Tsang, P.; Yamada, N. A.; Yasui, D. H.; LaSalle, J. M. A Prader-Willis locus lncRNA cloud modulates diurnal genes and energy expenditure. Hum. Mol. Genet. 2013, 22, 4318-4328.
54. Shende, V. R.; Goldrick, M. M.; Ramani, S.; Earnest, D. J. Expression and rhythmic modulation of circulating microRNAs targeting the clock gene Bmal1 in mice. PLoS One 2011, 6, e22586.
55. Nagel, R.; Clijsters, L.; Agami, R. the miRNA-192/194 cluster regulates the Period gene family and the circadian clock. FEBS J. 2009, 276, 5447-5455.
56. Na, Y. J.; Sung, J. H.; Lee, S. C.; Lee, Y. J.; Choi, Y. J.; Park, W. Y.; Shin, H. S.; Kim, J. H. Comprehensive analysis of microRNA-mRNA co-expression in circadian rhythm. Exp. Mol. Med. 2009, 41, 638-647.
57. Gatfield, D.; le Martelot, G.; Vejnar, C. E.; Gerlach, D.; Schaad O.; Fleury-Olela, F.; Ruskeepää, A. L.; Oresic, M.; Esau, C. C.; Zdobnov, E. M.; et al. Integration of microRNA miR-122 in hepatic circadian gene expression. Genes Dev. 2009, 23, 1313-1326.
58. Kojima, S.; Gatfield, D.; Esau, C. C.; Green, C. B. MicroRNA-122 modulates the rhythmic expression profile of the circadian deadenylase Nocturnin in mouse liver. PLoS One 2010, 5, e11264.
59. Wang, Y.; Osterbur, D. L.; Megaw, P. L.; Tosini, G.; Fukuhara, C.; Green, C. B.; Besharse, J. C. Rhythmic expression of Nocturnin mRNA in multiple tissues of the mouse. BMC Dev. Biol. 2001, 1, 9.
60. Barbot, W.; Wasowicz, M.; Dupressoir, A.; Versaux-Botteri, C.; Heidmann, T. A murine gene with circadian expression revealed by transposon insertion: Self-sustained rhythmicity in the liver and the photoreceptors. Biochim. Biophys. Acta 2002, 1576, 81-91.
61. Kojima, S.; Sher-Chen, E. L.; Green, C. B. Circadian control of mRNA polyadenylation dynamics regulates rhythmic protein expression. Genes Dev. 2012, 26, 2724-2736.
62. Oishi, K.; Miyazaki, K.; Kadota, K.; Kikuno, R.; Nagase, T.; Atsumi, G.; Ohkura, N.; Azama, T.; Mesaki, M.; Yukimasa, S.; et al. Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes. J. Biol. Chem. 2003, 278, 41519-41527.
63. Li, R.; Yue, J.; Zhang, Y.; Zhou, L.; Hao, W.; Yuan, J.; Qiang, B.; Ding, J. M.; Peng, X.; Cao, J. M. CLOCK/BMAL1 regulates human nocturnin transcription through binding to the E-box of nocturnin promoter. Mol. Cell. Biochem. 2008, 317, 169-177.
64. Vollmers, C.; Schmitz, R. J.; Nathanson, J.; Yeo, G.; Ecker, J. R.; Panda, S. Circadian oscillations of protein-coding and regulatory RNAs in a highly dynamic mammalian liver epigenome. Cell Metab. 2012, 16, 833-845.
65. +-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 2008, 134, 329-340.
66. Grimaldi, B.; Nakahata, Y.; Kaluzova, M.; Masubuchi, S.; Sassone-Corsi, P. Chromatin remodeling, metabolism and circadian clocks: The interplay of CLOCK and SIRT1. Int. J. Biochem. Cell Biol. 2009, 41, 81-86.
67. + salvage pathway by CLOCK-SIRT1. Science 2009, 324, 654-657.
68. +, SIRT1, and the circadian clock. Cold Spring Harb. Symp. Quant. Biol. 2011, 76, 31-38.
69. Sahar, S.; Sassone-Corsi, P. The epigenetic language of circadian clocks. Handb. Exp. Pharmacol. 2013, 217, 29-44.
70. Duong, H. A.; Robles, M. S.; Knutti, D.; Weitz, C. J. A molecular mechanism for circadian clock negative feedback. Science 2011, 332, 1436-1439.
71. Brown, S. A.; Ripperger, J.; Kadener, S.; Fleury-Olela, F.; Vilbois, F.; Rosbach, M.; Schibler, U. PERIOD1-associated proteins modulate the negative limb of the mammalian circadian oscillator. Science 2005, 308, 693-696.
72. Kowalska, E.; Ripperger, J. A.; Muheim, C.; Maier, B.; Kurihara, Y.; Fox, A. H.; Kramer, A.; Brown, S. A. Distinct roles of DBHS family members in the circadian transcriptional feedback loop. Mol. Cell. Biol. 2012, 32, 4585-4594.
73. Kowalska, E.; Ripperger, J. A.; Hoegger, D. C.; Bruegger, P.; Buch, T.; Birchler; T.; Mueller, A.; Albrecht, U.; Contaldo, C.; Brown, S. A. NONO couples the circadian clock to the cell cycle. Proc. Natl. Acad. Sci. USA 2013, 110, 1592-1599.
74. Guillaumond, F.; Boyer, B.; Becquet, D.; Guillen, S.; Kuhn, L.; Garin, J.; Belghazi, M.; Bosler, O.; Franc, J. L.; François-Bellan, A. M. Chromatin remodeling as a mechanism for circadian prolactin transcription: Rhythmic NONO and SFPQ recruitment to HLTF. FASEB J. 2011, 25, 2740-2756.
75. Torres-Farfan, C.; Serón-Ferré, M.; Dinet, V.; Korf, H. W. Immunocytochemical demonstration of day/night changes of clock gene protein levels in the murine adrenal gland: Differences between melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. J. Pineal Res. 2006, 40, 64-70.
76. Gutierrez-Cuesta, J.; Tajes, M.; Jiménez, A.; Coto-Montes, A.; Camins, A.; Pallàs, M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J. Pineal Res. 2008, 45, 497-505.
77. Chang, H.-M.; Wu, U.-I.; Lan, C.-T. Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J. Pineal Res. 2009, 47, 211-220.
78. Tajes, M.; Gutierrez-Cuesta, J.; Ortuño-Sahagun, D.; Camins, A.; Pallàs, M. Anti-aging properties of melatonin in an in vitro murine senescence model: Involvement of the sirtuin 1 pathway. J. Pineal Res. 2009, 47, 228-237.
79. Dubocovich, M. L.; Rivera-Bermudez, M. A.; Gerdin, M. J.; Masana, M. I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. 2003, 8, d1093-d1108.
80. 2 melatonin receptors in mammals. Endocrine 2005, 27, 101-110.
81. Goel, N.; Stunkard, A. J.; Rogers, N. L.; van Dongen, H. P.; Allison, K. C.; O'Reardon, J. P.; Ahima, R. S.; Cummings, D. E.; Heo, M.; Dinges, D. F. Circadian rhythm profiles in women with night eating syndrome. J. Biol. Rhythm. 2009, 24, 85-94.
82. Escames, G.; López, L. C.; Tapias, V.; Utrilla, P.; Reiter, R. J.; Hitos, A. B.; León, J.; Rodríguez, M. I.; Acuña-Castroviejo, D. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J. Pineal Res. 2006, 40, 71-78.
83. López, L. C.; Escames, G.; Tapias, V.; Utrilla, P.; León, J.; Acuña-Castroviejo, D. Identification of an inducible nitric oxide synthase in diaphragm mitochondria from septic mice: Its relation with mitochondrial dysfunction and prevention by melatonin. Int. J. Biochem. Cell Biol. 2006, 38, 267-278.
84. 1-acetyl-5-methoxykynuramine prevent mitochondrial nitric oxide synthase induction in parkinsonian mice. J. Neurosci. Res. 2009, 87, 3002-3010.
85. Kawai, M.; Green, C. B.; Lecka-Czernik, B.; Douris, N.; Gilbert, M. R.; Kojima, S.; Ackert-Bicknell, C.; Garg, N.; Horowitz, M. C.; Adamo, M. L; et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPARγ nuclear translocation. Proc. Natl. Acad. Sci. USA 2010, 107, 10508-10513.
86. Lewy, A. J.; Wehr, T. A.; Goodwin, F. K.; Newsome, D. A.; Markey S. P. Light suppresses melatonin secretion in humans. Science 1980, 210, 1267-1269.
87. Reiter, R. J. The melatonin rhythm: Both a clock and a calendar. Experientia 1993, 49, 654-664.
88. Klein, D. C. Arylalkylamine N-acetyltransferase: "The timezyme". J. Biol. Chem. 2007, 282, 4233-4237.
89. Reiter, R. J.; Tan, D.-X.; Korkmaz, A.; Erren, T. C.; Piekarski, C.; Tamura, H.; Manchester, L. C. Light at night, chronodisruption, melatonin suppression, and cancer risk: A review. Crit. Rev. Oncog. 2007, 13, 303-328.
90. Erren, T. C.; Reiter, R. J. Light hygiene: Time to make preventive use of insights-old and new-into the nexus of the drug light, melatonin, clocks, chronodisruption and public health. Med. Hyptheses 2009, 73, 537-541.
91. Stevens, R. G. Working against our endogenous circadian clock: Breast cancer and electric lighting in the modern world. Mutat. Res. 2009, 680, 106-108.
92. Reiter, R. J.; Tan, D.-X.; Erren, T. C.; Fuentes-Broto, L.; Paredes, S. D. Light-mediated perturbations of circadian timing and cancer risk: A mechanistic analysis. Integr. Cancer Ther. 2009, 8, 354-360.
93. Anisimov, V. N.; Vinogradova, I. A.; Panchenko, A. V.; Popovich, I. G.; Zabezhinski, M. A. Light-at-night-induced circadian disruption, cancer and aging. Curr. Aging Sci. 2012, 5, 170-177.
94. Reiter, R. J.; Tan, D.-X.; Korkmaz, A.; Ma, S. Obesity and metabolic syndrome: Association with chronodisruption, sleep deprivation, and melatonin suppression. Ann. Med. 2012, 44, 564-577.
95. Zhu, Y.; Stevens, R. G.; Hoffman, A. E.; Tjonneland, A.; Vogel, U. B.; Zheng, T.; Hansen, J. Epigenetic impact of long-term shiftwork: Pilot evidence from circadian genes and whole-genome methylation analysis. Chronobiol. Int. 2011, 28, 852-861.
96. Jacobs, D. I.; Hansen, J.; Fu, A.; Stevens, R. G.; Tjonneland, A.; Vogel, U. B.; Zheng, T.; Zhu, Y. Methylation alterations at imprinted genes detected among long-term shiftworkers. Environ. Mol. Mutagen. 2013, 54, 141-146.
97. Schwimmer, H.; Metzer, A.; Pilosof, Y.; Szyf, M.; Machnes, Z. M.; Fares, F.; Harel, O.; Haim, A. Light at night and melatonin have opposite effects on breast cancer tumors in mice assessed by growth rates and global DNA methylation. Chronobiol. Int. 2014, 31, 144-150.
98. Peschke, E. Melatonin, endocrine pancreas and diabetes. J. Pineal Res. 2008, 44, 26-40.
99. Shieh, J.-M.; Wu, H.-T.; Cheng, K.-C.; Cheng, J.-T. Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCζ-Akt-GSK3β pathway in hepatic cells. J. Pineal Res. 2009, 47, 339-344.
100. Peschke, E.; Mühlbauer, E. New evidence for a role of melatonin in glucose regulation. Best Pract. Res. Clin. Endocrinol. Metab. 2010, 24, 829-841.
101. Hardeland, R. Melatonin and the theories of aging: A critical appraisal of melatonin's role in antiaging mechanisms. J. Pineal Res. 2013, 55, 325-356.
102. Corbalán-Tutau, D.; Madrid, J. A.; Nicolás, F.; Garaulet, M. Daily profile of two circadian markers "melatonin and cortisol" and associations with metabolic syndrome components. Physiol. Behav. 2014, 123, 231-235.
103. Takahashi, S.; Inoue, I.; Nakajima, Y.; Seo, M.; Nakano, T.; Yang, F.; Kimagai, M.; Komoda, T.; Awata, T.; Ikeda, M.; et al. A promoter in the novel exon of hPPARγ directs the circadian expression of PPARγ. J. Atheroscler. Thromb. 2010, 17, 73-83.
104. Zhang, L.; Su, P.; Xu, C.; Chen, C.; Liang, A.; Du, K.; Peng, Y.; Huang, D. Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J. Pineal Res. 2010, 49, 364-372.
105. Alonso-Vale, M. I. C.; Peres, S. B.; Vernochet, C.; Farmer, S. R.; Lima, F. B. Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPβ transcriptional activity. J. Pineal Res. 2009, 47, 221-227.
106. González, A.; Alvarez-García, V.; Martínez-Campa, C.; Alonso-González, C.; Cos, S. Melatonin promotes differentiation of 3T3-L1 fibroblasts. J. Pineal Res. 2012, 52, 12-20.
107. De Luxán-Delgado, B.; Caballero, B.; Potes, Y.; Rubio-González, A.; Rodríguez, I.; Gutiérrez-Rodríguez, J.; Solano, J. J.; Coto-Montes, A. Melatonin administration decreases adipogenesis in the liver of ob/ob mice through autophagy modulation. J. Pineal Res. 2014, 56, 126-133.
108. Tan, D.-X.; Manchester, L. C.; Fuentes-Broto, L.; Paredes, S. D.; Reiter, R. J. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: Relation to human obesity. Obes. Rev. 2011, 12, 167-188.
109. Jiménez-Aranda, A.; Fernández-Vázquez, G.; Campos, D.; Tassi, M.; Velasco-Perez, L.; Tan, D.-X.; Reiter, R. J.; Agil, A. Melatonin induces browning of inguinal adipose tissue in Zucker diabetic fatty rats. J. Pineal Res. 2013, 55, 416-423.
110. Vinogradova, I.; Anisimov, V. Melatonin prevents the development of the metabolic syndrome in male rats exposed to different light/dark regimes. Biogerontology 2013, 14, 401-409.
111. Douris, N.; Kojima, S.; Pan, X.; Lerch-Gaggl, A. F.; Duong, S. Q.; Hussain, M. M.; Green, C. B. Nocturnin regulates circadian trafficking of dietary lipid in intestinal enterocytes. Curr. Biol. 2011, 21, 1347-1355.
112. Hussain, M. M.; Pan, X. Clock regulation of dietary lipid absorption. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 336-341.
113. Douris, N.; Green, C. B. NOC out the fat: A short review of the circadian deadenylase Nocturnin. Ann. Med. 2008, 40, 622-626.
114. Kawai, M.; Rosen, C. J. PPARγ: A circadian transcription factor in adipogenesis and osteogenesis. Nat. Rev. Endocrinol. 2010, 6, 629-636.
115. Lecka-Czernik, B.; Rosen, C. J.; Kawai, M. Skeletal aging and the adipocyte program. Cell Cycle 2010, 9, 3648-3654.
116. Guntur, A. R.; Kawai, M.; Le, P.; Bouxsein, M. L.; Bornstein, S.; Green, C. B.; Rosen, C. J. An essential role for the circadian-regulated gene Nocturnin in osteogenesis: The importance of local timekeeping in skeletal homeostasis. Ann. N. Y. Acad. Sci. 2011, 1237, 58-63.
117. Kawai, M.; Delany, A. M.; Green, C. B.; Adamo, M. L.; Rosen, C. J. Nocturnin suppresses igf1 expression in bone by targeting the 3'-untranslated region of igf1 mRNA. Endocrinology 2010, 151, 4861-4870.
118. Sethi, S.; Radio, N. M.; Kotlarczyk, M. P.; Chen, C. T.; Wei, Y. H.; Jockers, R.; Witt-Enderby, P. A. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J. Pineal Res. 2010, 49, 222-238.
119. Park, K.-H.; Kang, J. W.; Lee, E. M.; Kim, J. S.; Rhee, Y. H.; Kim, M.; Jeong, S. J.; Park, Y. G.; Kim, S. H. Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J. Pineal Res. 2011, 51, 187-194.
120. Zhang, L.; Zhang, J.; Ling, Y.; Chen, C.; Liang, A.; Peng, Y.; Chang, H.; Su, P.; Huang, D. Sustained release of melatonin from poly (lactic-co-glycolic acid) (PLGA) microspheres to induce osteogenesis of human mesenchymal stem cells in vitro. J. Pineal Res. 2013, 54, 24-32.
121. Aravamudhan, A.; Ramos, D. M.; Nip, J.; Subramanian, A.; James, R.; Harmon, M. D.; Yu, X.; Kumbar, S. G. Osteoinductive small molecules: Growth factor alternatives for bone tissue engineering. Curr. Pharm. Des. 2013, 19, 3420-3428.
122. Zhao, Q.-H.; Wang, S.-G.; Liu, S.-X.; Li, J.-P.; Zhang, Y.-X.; Sun, Z.-Y.; Fan, Q.-M.; Tian, J.-W. PPARγ forms a bridge between DNA methylation and histone acetylation at the C/EBPα gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells. FEBS J. 2013, 280, 5801-5814.
123. Hemming, S.; Cakouros, D.; Isenmann, S.; Cooper, L.; Menicanin, D.; Zannettino, A.; Gronthos, S. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells 2014, 32, 802-815.
124. Garbarino-Pico, E.; Green, C. B. Posttranscriptional regulation of mammalian circadian clock output. Cold Spring Harb. Symp. Quant. Biol. 2007, 72, 145-156.
125. Hee, S.-W.; Tsai, S.-H.; Chang, Y.-C.; Chang, C.-J.; Yu, I.-S.; Lee, P.-C.; Lee, W.-J.; Chang, Y.-C. E.; Chuang, L.-M. The role of nocturnin in early adipogenesis and modulation of sytemic insulin resistance in human. Obesity 2012, 20, 1558-1565.
126. Garbarino-Pico, E.; Niu, S.; Rollag, M. D.; Strayer, C. A.; Besharse, J. C.; Green, C. B. Immediate early response of the circadian polyA ribonuclease nocturnin to two extracellular stimuli. RNA 2007, 13, 745-755.
127. Massiera, F.; Barbry, P.; Guesnet, P.; Joly, A.; Luquet, S.; Moreilhon-Brest, C.; Mohsen-Kanson, T.; Amri, E.-Z.; Ailhaud, G. A Western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J. Lipid Res. 2010, 51, 2352-2361.
128. Hardeland, R. Antioxidative protection by melatonin-Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005, 27, 119-130.
129. Hardeland, R. Melatonin and its metabolites as anti-nitrosating and anti-nitrating agents. J. Exp. Integr. Med. 2011, 1, 67-81.
130. Arese, M.; Magnifico, M. C.; Mastronicola, D.; Altieri, F.; Grillo, C.; Blanck, T. J. J.; Sarti, P. Nanomolar melatonin enhances nNOS expression and controls HaCaT-cells bioenergetics. IUBMB Life 2012, 64, 251-258.
131. Sarti, P.; Magnifico, M. C.; Altieri, F.; Mastronicola, D.; Arese, M. New evidence for cross talk between melatonin and mitochondria mediated by a circadian-compatible interaction with nitric oxide. Int. J. Mol. Sci. 2013, 14, 11259-11276.
132. Cencioni, C.; Spallotta, F.; Martelli, F.; Valente, S.; Mai, A.; Zeiher, A. M.; Gaetano, C. Oxidative stress and epigenetic regulation in ageing and age-related diseases. Int. J. Mol. Sci. 2013, 14, 17643-17663.
133. Ito, T.; Yagi, S.; Yamakuchi, M. MicroRNA-34a regulation of endothelial senescence. Biochem. Biophys. Res. Commun. 2010, 398, 735-740.
134. Boon, R. A.; Iekushi, K.; Lechner, S.; Seeger, T.; Fischer, A.; Heydt, S.; Kaluza, D., Treguer, K.; Carmona, G.; Bonauer, A.; et al. MicroRNA-34a regulates cardiac ageing and function. Nature 2013, 35, 107-119.
135. Reiter, R. J.; Tan, D.-X.; Paredes, S. D.; Fuentes-Broto, L. Beneficial effects of melatonin in cardiovascular disease. Ann. Med. 2010, 42, 276-285.
136. Dominguez-Rodriguez, A. Melatonin in cardiovascular disease. Expert Opin. Investig. Drugs 2012, 21, 1593-1596.
137. Lochner, A.; Huisamen, B.; Nduhirabandi, F. Cardioprotective effect of melatonin against ischemia/reperfusion damage. Front. Biosci. 2013, 5, 305-315.
138. Magenta, A.; Cencioni, C.; Fasanaro, P.; Zaccagnini, G.; Greco, S.; Sarra-Ferraris, G.; Antonini, A.; Martelli, F.; Capogrossi, M. C. miR-200c is up-regulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ. 2011, 18, 1628-1639.
139. Cabrer, J.; Burkhardt, S.; Tan, D.-X.; Manchester, L. C.; Karbownik, M.; Reiter, R. J. Autoxidation and toxicant-induced oxidation of lipid and DNA in monkey liver: Reduction of molecular damage by melatonin. Pharmacol. Toxicol. 2001, 89, 225-230.
140. López-Burillo, S.; Tan, D.-X.; Mayo, J. C.; Sainz, R. M.; Manchester, L. C.; Reiter, R. J. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and α-lipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: A study of their individual and synergistic actions. J. Pineal Res. 2003, 34, 269-277.
141. Korkmaz, A.; Topal, T.; Oter, S.; Tan, D.-X.; Reiter, R. J. Hyperglycemia-related pathophysiologic mechanisms and potential beneficial actions of melatonin. Mini-Rev. Med. Chem. 2008, 8, 1144-1153.
142. Korkmaz, A.; Kunak, Z. I.; Paredes, S. D.; Yaren, H.; Tan, D.-X.; Reiter, R. J. The use of melatonin to combat mustard toxicity. Neuroendocrinol. Lett. 2008, 29, 614-619.
143. Natarajan, M.; Sadeghi, K.; Reiter, R. J.; Meltz, M. L. The neurohormone melatonin inhibits cytokine, mitogen, and ionizing radiation induced NF-κB. Biochem. Mol. Biol. Int. 1995, 37, 1063-1070.
144. Deng, W. G.; Tang, S. T.; Tseng, H. P.; Wu, K. K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108, 518-524.
145. Chuang, J. I.; Natarajan, M.; Meltz, M. L.; Reiter, R. J. Effect of melatonin on NF-κB DNA-binding activity in the rat spleen. Cell Biol. Int. 1996, 20, 687-692.
146. Choi, J. D.; Lee, J. S. Interplay between epigenetics and genetics in cancer. Genomics Inf. 2013, 11, 164-173.
147. Tam, W. L.; Weinberg, R. A. The epigenetics of endothelial-mesenchymal plasticity in cancer. Nat. Med. 2013, 19, 1438-1449.
148. Jeong, H. M.; Kwon, M. J.; Shin, Y. K. Over-expression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front. Oncol. 2014, 4, 12.
149. Kanai, Y.; Arai, E. Multilayer-omics analyses of human cancers: Exploration of biomarkers and drug targets based in the activities of the International Human Epigenome Consortium. Front. Genet. 2014, 5, 24.
150. Huarte, M.; Rinn, J. L. Large non-coding RNAs: Missing links to cancer? Hum. Mol. Genet. 2010, 19, R152-R161.
151. Hung, T.; Chang, H. Y. Long noncoding RNA in genome regulation: Prospects and mechanisms. RNA Biol. 2010, 7, 583-585.
152. Ye, C.; Li, L. 5-Hydroxymethylcytosine: A new insight into epigenetics in cancer. Cancer Biol. Ther. 2014, 15, 10-15.
153. Wu, Y. C.; Ling, Z. Q. The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histol. Histopathol. 2014, 29, 991-997.
154. Lam, L. L.; Emberly, E.; Fraser, H. B.; Neumann, S. M.; Chen, E.; Miller, G. E.; Kobor, M. S. Factors underlying variable DNA methylation in human community cohort. Proc. Natl. Acad. Sci. USA 2012, 109, 17253-17260.
155. Stankiewicz, A. M.; Swiergiel, A. H.; Lisowski, P. Epigenetics of stress adaptations in the brain. Brain Res. Bull. 2013, 98, 76-92.
156. Klengel, T.; Pape, J.; Binder, E. B.; Mehta, D. The role of DNA methylation in stress-related psychiatric disorders. Neuropharmacology 2014, 80, 115-132.
157. Vojta, A.; Zoldož, V. Adaptation or malignant transformation: The two faces of epigenetically mediated responses to stress. Biomed. Res. Int. 2013, 2013, 954060.
158. Bob, P.; Fedor-Freybergh, P. Melatonin, consciousness, and traumatic stress. J. Pineal Res. 2008, 44, 341-347.
159. Haridas, S.; Kumar, M.; Manda, K. Melatonin ameliorates chronic mild stress induced behavioral dysfunctions in mice. Physiol. Behav. 2013, 119, 201-207.
160. Muller, M. D.; Sauder, C. L.; Ray, C. A. Melatonin attenuates the skin sympathetic nerve response to mental stress. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1382-H1386.
161. Ruksee, N.; Tongjaroenbuangam, W.; Mahanam, T.; Govitrapong, P. Melatonin pretreatment prevented the effect of dexamethasone negative alterations on behavior and hippocampal neurogenesis in the mouse brain. J. Steroid Biochem. Mol. Biol. 2014, 143C, 72-80.
162. Bosch-Presegué, L.; Vaquero, A. Sirtuins in stress response: Guardians of the genome. Oncogene 2014, 33, 3764-3775.
163. Bosch-Presegué, L.; Vaquero, A. The dual role of sirtuins in cancer. Genes Cancer 2011, 2, 648-662.
164. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R., Alt, F. W.; Schibler, U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 2008, 134, 317-328.
165. Joshi, P.; Quach, O. L.; Giguere, S. S.; Cristea, I. M. A functional proteomics perspective of DBC1 as a regulator of transcription. J. Prot. Bioinform. 2013, (Suppl. 2), 002.
166. Jung-Hynes, B.; Nihal, M.; Zhong, W.; Ahmad, N. Role of histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J. Biol. Chem. 2009, 284, 3823-3832.
167. Jung-Hynes, B.; Ahmad, N. SIRT1 controls circadian clock circuitry and promotes cell survival: A connection with age-related neoplasms. FASEB J. 2009, 23, 2803-2809.
168. Jung-Hynes, B.; Reiter, R. J.; Ahmad, N. Sirtuins, melatonin and circadian rhythms: Building a bridge between aging and cancer. J. Pineal Res. 2010, 48, 9-19.
169. Jung-Hynes, B.; Schmit, T. L.; Reagan-Shaw, S. R.; Siddiqui, I. A.; Mukhtar, H.; Ahmad, N. Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J. Pineal Res. 2011, 50, 140-149.
170. Hill, S. M.; Frasch, T.; Xiang, S.; Yuan, L.; Duplessis, T.; Mao, L. Molecular mechanisms of melatonin anticancer effects. Integr. Cancer Ther. 2009, 8, 337-346.
171. Lee, S. E.; Kim, S. J.; Youn, J.-P.; Hwang, S. Y.; Park, C.-S.; Park, Y. S. MicroRNA and gene expression analysis of melatonin-exposed breast cancer cell lines indicating involvement of the anticancer effect. J. Pineal Res. 2011, 51, 345-352.
172. Lee, S. E.; Kim, S. J.; Youn, J.-P.; Yu, S. Y.; Yang, H.; Jeong, S. I.; Hwang, S. Y.; Park, C.-S.; Park, Y. S. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. J. Pineal Res. 2013, 54, 80-88.
173. Sweatt, J. D. The emerging field of neuroepigenetics. Neuron 2013, 80, 624-632.
174. Zhao, Y. Q.; Jordan, I. K.; Kunyak, V. V. Epigenetics components of aging in the central nervous system. Neurotherapeutics 2013, 10, 647-663.
175. Guzman-Karlsson, M. C.; Meadows, J. P.; Gavin, C. F.; Hablitz, J. J.; Sweatt, J. D. Transcriptional and epigenetic regulation of Hebbian and non-Hebbian plasticity. Neuropharmacology 2014, 80, 3-17.
176. Rudenko, A.; Tsai, L. H. Epigenetic modifications in the nervous system and their impact upon cognitive impairments. Neuropharmacology 2014, 80, 70-82.
177. Saab, B. J.; Mansuy, I. M. Neuroepigenetics of memory formation and impairment: The role of microRNAs. Neuropharmacology 2014, 80, 61-69.
178. Detanico, B. C.; Piato, A. L.; Freitas, J. J.; Lhullier, F.-L.; Hidalgo, M. P.; Caumo, W.; Elisabetsky, E. Antidepressant-like effects of melatonin in the mouse chronic mild stress model. Eur. J. Pharmacol. 2009, 607, 121-125.
179. Srinivasan, V.; Pandi-Perumal, S. R.; Trakht, I.; Spence, D. W.; Hardeland, R.; Poeggeler, B.; Cardinali, D. P. Pathophysiology of depression: Role of sleep and the melatonergic system. Psychiatr. Res. 2009, 165, 201-214.
180. Maldonado, M. D.; Reiter, R. J.; Pérez-San-Gregorio, M. A. Melatonin as a potential therapeutic agent in psychiatric illness. Hum. Psychopharmacol. 2009, 24, 391-400.
181. Hardeland, R. Melatonin in aging and disease-Multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012, 3, 194-225.
182. Morley-Fletcher, S.; Mairesse, J.; Soumier, A.; Banasr, M.; Fagioli, F.; Gabriel, C.; Mocaer, E.; Daszuta, A.; McEwen, B.; Nicoletti, F.; et al. Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats. Psychopharmacology 2011, 217, 301-313.
183. Irmak, M. K.; Sizlan, A. Essential hypertension seems to result from melatonin-induced epigenetic modifications in area postrema. Med. Hypotheses 2006, 66, 1000-1007.
184. Irmak, M. K.; Topal, T.; Oter, S. Melatonin seems to be a mediator that transfers the environmental stimuli to oocytes for inheritance of adaptive changes through epigenetic inheritance system. Med. Hypotheses 2005, 64, 1138-1143.
185. Niles, L. P.; Pan, Y.; Kang, S.; Lacoul, A. Melatonin induces histone hyperacetylation in the rat brain. Neurosci. Lett. 2013, 541, 49-53.
186. Sharma, R.; Ottenhof, T.; Rzeczkowska, P. A.; Niles, L. P. Epigenetic targets for melatonin: Induction of histone H3 hyperacetylation and gene expression in C17. 2 neural stem cells. J. Pineal Res. 2008, 45, 277-264.
187. Sarlak, G.; Jenwitheesuk, A.; Chetsawang, B.; Govitrapong, P. Effects of melatonin on nervous system aging: Neurogenesis and neurodegeneration. J. Pharmacol. Sci. 2013, 123, 9-24.
188. Meng, F.; Dai, E.; Zhang, Y.; Chen, X.; Liu, X.; Wang, S.; Wang, L.; Jiang, W. Constructing and characterizing a bioactive small molecule and microRNA association network for Alzheimer's disease. J. R. Soc. Interface 2013, 11, 20131057.
189. Bacalini, M. G.; Friso, S.; Olivieri, F.; Pirazzini, C.; Guiliani, C.; Capri, M.; Santoro, A.; Franceschi, C.; Garagnani, P. Present and future of anti-ageing epigenetic diets. Mech. Ageing Dev. 2014, 136, 101-115.
190. Wang, X.; Wang, Z.-H.; Wu, Y.-Y.; Tang, H.; Tan, L.; Wang, X.; Gao, X.-Y.; Xiong, Y.-S.; Liu, D.; Wang, J.-Z.; et al. Melatonin attenuates scopolamine-induced memory/synaptic disorder by rescuing EPACs/miR-124/Egr1 pathway. Mol. Neurobiol. 2013, 47, 373-381.
191. Wilkinson, B.; Campbell, D. B. Contribution of long non-coding RNAs to autism spectrum disorders risk. Int. Rev. Neurobiol. 2013, 113, 35-59.
192. Lanfumey, L.; Mongeau, R.; Hamon, M. Biological rhythms and melatonin in mood disorders and their treatments. Pharmacol. Ther. 2013, 138, 176-184.
193. Dodd, S.; Maes, M.; Anderson, G.; Dean, O. M.; Moylan, S.; Berk, M. Putative neuroprotective agents in neuropsychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42, 135-145.
194. Vogel-Ciernia, A.; Wood, M. A. Neuron-specific chromatin remodeling: A missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology 2014, 80, 18-27.
195. Millan, M. J. On "polypharmacy" and multi-target agents, complementary strategies for improving the treatment of depression: A comparative appraisal. Int. J. Neuropsychopharmacol. 2014, 17, 1009-1037.
196. Schmitt, A.; Malchow, B.; Hasan, A.; Falkai, P. The impact of environmental factors in severe psychiatric disorders. Front. Neurosci. 2014, 8, 19.
197. Orozco-Solis, R.; Sassone-Corsi, P. Epigenetic control and the circadian clock: Linking metabolism to neuronal responses. Neuroscience 2014, 264C, 76-87.
198. Akula, N.; Barb, J.; Jiang, X.; Wendland, J. R.; Choi, K. H.; Sen, S. K.; Hou, L.; Chen, D. T. W.; Laje, G.; Johnson, K.; et al. RNA-sequencing of the brain transcriptome implicates dysregulation of neuroplasticity, circadian rhythms and GTPase binding in bipolar disorder. Mol. Psychiatry 2014, doi: 10. 1038/mp. 2013. 170.